Date: 2011-03-17
Type of information: Development agreement
Compound: PC-mAb (monoclonal antibody to phosphorylcholine)
Company: Lonza (Switzerland) Athera Biotechnologies (Sweden)
Therapeutic area: Cardiovascular diseases
Type agreement: development
manufacturing
production
Action mechanism:
Disease: acute coronary syndrom
Details: Lonza has signed a new development and manufacturing agreement with Athera Biotechnologies AB, part of the Karolinska Development AB portfolio. Lonza will initiate cell line and process development for Athera’s monoclonal antibody PC-mAb. Athera’s PC-mAb is intended for the treatment of patients with Acute Coronary Syndrome who are at an increased risk of secondary cardiovascular events and death. This agreement secures a development and cGMP manufacturing plan for Athera. Lonza will initiate cell line and process development, using Lonza’s GS Gene Expression System.
PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody developed for Athera by Dyax Corp. in Boston, USA. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.
Financial terms:
Latest news:
